C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a mutant dystrophin protein. DMD patients undergo gradual progressive paralysis until death. Chronic glucocorticoid therapy remains one of the main treatments for DMD, despite the significant side effects. However, its mech...

Full description

Bibliographic Details
Main Authors: Jie Chen, Xinsheng Lai
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Bioengineered
Subjects:
Online Access:http://dx.doi.org/10.1080/21655979.2021.1967029
_version_ 1798034031030304768
author Jie Chen
Xinsheng Lai
author_facet Jie Chen
Xinsheng Lai
author_sort Jie Chen
collection DOAJ
description Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a mutant dystrophin protein. DMD patients undergo gradual progressive paralysis until death. Chronic glucocorticoid therapy remains one of the main treatments for DMD, despite the significant side effects. However, its mechanisms of action remain largely unknown. We used bioinformatics tools to identify pathogenic genes involved in DMD and glucocorticoid target genes. Two gene expression profiles containing data from DMD patients and healthy controls (GSE38417 and GSE109178) were downloaded for further analysis. Differentially expressed genes (DEGs) between DMD patients and controls were identified using GEO2R, and glucocorticoid target genes were predicted from the Pharmacogenetics and Pharmacogenomics Knowledge Base. Surprisingly, only one gene, CXCL12 (C–X–C motif chemokine ligand 12), was both a glucocorticoid target and a DEG. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis, Gene Ontology term enrichment analysis, and gene set enrichment analysis were performed. A protein–protein interaction network was constructed and hub genes identified using the Search Tool for the Retrieval of Interacting Genes (STRING) database and Cytoscape. Enriched pathways involving the DEGs, including CXCL12, were associated with the immune response and inflammation. Levels of CXCL12 and its receptor CXCR4 (C–X–C motif chemokine receptor 4) were increased in X-linked muscular dystrophy (mdx) mice (DMD models) but became significantly reduced after prednisone treatment. Metformin also reduced the expression of CXCL12 and CXCR4 in mdx mice. In conclusion, the CXCL12–CXCR4 pathway may be a potential target for DMD therapy.
first_indexed 2024-04-11T20:38:34Z
format Article
id doaj.art-1dca640111384bc8a9c1a6c3d212ae70
institution Directory Open Access Journal
issn 2165-5979
2165-5987
language English
last_indexed 2024-04-11T20:38:34Z
publishDate 2021-01-01
publisher Taylor & Francis Group
record_format Article
series Bioengineered
spelling doaj.art-1dca640111384bc8a9c1a6c3d212ae702022-12-22T04:04:18ZengTaylor & Francis GroupBioengineered2165-59792165-59872021-01-011215428543910.1080/21655979.2021.19670291967029C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophyJie Chen0Xinsheng Lai1School of Life Science, Nanchang UniversitySchool of Life Science, Nanchang UniversityDuchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a mutant dystrophin protein. DMD patients undergo gradual progressive paralysis until death. Chronic glucocorticoid therapy remains one of the main treatments for DMD, despite the significant side effects. However, its mechanisms of action remain largely unknown. We used bioinformatics tools to identify pathogenic genes involved in DMD and glucocorticoid target genes. Two gene expression profiles containing data from DMD patients and healthy controls (GSE38417 and GSE109178) were downloaded for further analysis. Differentially expressed genes (DEGs) between DMD patients and controls were identified using GEO2R, and glucocorticoid target genes were predicted from the Pharmacogenetics and Pharmacogenomics Knowledge Base. Surprisingly, only one gene, CXCL12 (C–X–C motif chemokine ligand 12), was both a glucocorticoid target and a DEG. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis, Gene Ontology term enrichment analysis, and gene set enrichment analysis were performed. A protein–protein interaction network was constructed and hub genes identified using the Search Tool for the Retrieval of Interacting Genes (STRING) database and Cytoscape. Enriched pathways involving the DEGs, including CXCL12, were associated with the immune response and inflammation. Levels of CXCL12 and its receptor CXCR4 (C–X–C motif chemokine receptor 4) were increased in X-linked muscular dystrophy (mdx) mice (DMD models) but became significantly reduced after prednisone treatment. Metformin also reduced the expression of CXCL12 and CXCR4 in mdx mice. In conclusion, the CXCL12–CXCR4 pathway may be a potential target for DMD therapy.http://dx.doi.org/10.1080/21655979.2021.1967029duchenne muscular dystrophybioinformatic analysisdifferentially expressed genescxcl12glucocorticoids
spellingShingle Jie Chen
Xinsheng Lai
C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy
Bioengineered
duchenne muscular dystrophy
bioinformatic analysis
differentially expressed genes
cxcl12
glucocorticoids
title C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy
title_full C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy
title_fullStr C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy
title_full_unstemmed C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy
title_short C–X–C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy
title_sort c x c motif chemokine ligand 12 a potential therapeutic target in duchenne muscular dystrophy
topic duchenne muscular dystrophy
bioinformatic analysis
differentially expressed genes
cxcl12
glucocorticoids
url http://dx.doi.org/10.1080/21655979.2021.1967029
work_keys_str_mv AT jiechen cxcmotifchemokineligand12apotentialtherapeutictargetinduchennemusculardystrophy
AT xinshenglai cxcmotifchemokineligand12apotentialtherapeutictargetinduchennemusculardystrophy